TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06793215: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06793215 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06793215 Rescue Dossier →